The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence- and consensus-based recommendations for a multidisciplinary approach for the management of patients with gastric cancer. For patients with resectable locoregional cancer, the guidelines recommend gastrectomy with a D1+ or a modified D2 lymph node dissection (performed by experienced surgeons in high-volume centers). Postoperative chemoradiation is the preferred option after complete gastric resection for patients with T3-T4 tumors and node-positive T1-T2 tumors. Postoperative chemotherapy is included as an option after a modified D2 lymph node dissection for this group of patients. Trastuzumab with chemotherapy is recommended as first-line therapy for patients with HER2-positive advanced or metastatic cancer, confirmed by immunohistochemistry and, if needed, by fluorescence in situ hybridization for IHC 2+. Copyright © 2013 by the National Comprehensive Cancer Network. All rights reserved.
CITATION STYLE
Ajani, J. A., Bentrem, D. J., Besh, S., D’Amico, T. A., Das, P., Denlinger, C., … Sundar, H. (2013). Gastric cancer, version 2.2013. JNCCN Journal of the National Comprehensive Cancer Network, 11(5), 531–546. https://doi.org/10.6004/jnccn.2013.0070
Mendeley helps you to discover research relevant for your work.